Core Viewpoint - A class action lawsuit has been filed against West Pharmaceutical Services, Inc. for allegedly making false statements and failing to disclose significant issues affecting its financial performance during the Class Period from February 16, 2023, to February 12, 2025 [1][3]. Group 1: Allegations of Misleading Statements - The lawsuit claims that West Pharmaceutical misrepresented its visibility into customer demand and attributed challenges to temporary COVID-related product destocking, while it was actually facing ongoing destocking in its High-Value Products portfolio [3]. - It is alleged that the SmartDose device, which was marketed as a high-margin growth product, negatively impacted profit margins due to operational inefficiencies [3]. - The lawsuit also points out that these margin pressures could lead to costly restructuring activities, including the company's exit from continuous glucose monitoring contracts with long-standing customers [3]. Group 2: Financial Forecast and Market Reaction - On February 13, 2025, West Pharmaceutical issued a revenue forecast for 2025 between $2.88 billion and $2.91 billion, which was significantly below market expectations [4]. - The disappointing guidance was attributed to challenges in Contract Manufacturing, including the loss of two major continuous glucose monitoring customers transitioning to in-house manufacturing [4]. - Following the announcement, West Pharmaceutical's stock price fell by more than 38% [4].

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc." or the "Company") (NYSE: WST) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of West Pharmaceutical Services, Inc. investors who were adversely affected by alleged securities fraud between February 16, 2023 and February 12, 2025. Follow the link below to get more information and be contacted by a ...

NEW YORK, May 8, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of West Pharmaceutical Services, Inc. (NYSE: WST).Shareholders who purchased shares of WST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/west-pharmaceutical-services-inc-loss-submission-form/?id=147325&from=4 CLAS ...